Dolutegravir is an integrase inhibitor that has a high antiviral activity and unique profile of resistance. In this report we described our experience with fourteen naïve HIV-infected patients who started dolutegravir monotherapy, rapidly achieving viral suppression. We analyzed CD4 lymphocytes and lipid profile finding a rapid immune restore and favorable metabolic impact. Despite this is an observational study of a little cohort of patients, it suggests the safety and efficacy of dolutegravir monotherapy.
To cite this article
Dolutegravir montherapy in HIV-infected naïve patients with <100,000 copies/ML HIV RNA load, an update of a little cohort in Verona
Infectious Diseases & Tropical Medicine 2016; 2 (2): e295
Submission date: 10 Jun 2016
Revised on: 18 Jun 2016
Accepted on: 04 Jul 2016
Published online: 11 Jul 2016